Abstract Library

Welcome to the open-access search for all ENETS abstracts presented at the Annual ENETS Conferences.

Everyone can browse the library to find basic information on abstracts. To get full access to each entry, you will be asked to log in to your myENETS account.

 

Please note:

Participants of the 2025 ENETS Conference enjoy full access to the 2025 conference digital resources through myENETS: the abstract booklet, e-posters and videos, slide decks of talks, the poster carousel, and more.

ENETS Abstract Search

#4590 Association of SST5TMD4 and SST5TMD5 expression with metastasis and poor prognostic markers in gastroenteropancreatic neuroendocrine tumours

Introduction: The expression of the somatostatin receptor isoform SST5TMD4 is linked to poorer prognosis in somatotropinomas, as well as in breast and thyroid cancers, and it is notably overexpressed in gastroenteropancreatic neuroendocrine tumours (GEP-NETs).

Conference:

Presenting Author: Pedraza-Arevalo S

Authors: Pedraza-Arévalo S, Díaz-Pérez J, Garcia-Carbonero R, Villabona C, Capdevila J,

Keywords: GEP-NET, somatostatin, truncated receptor, metastasis,

#4561 Prognostic value of pre-therapeutic and interim SSTR PET in patients with GI-NET receiving peptide receptor radionuclide therapy

Introduction: Baseline and interim (after 2 cycles) somatostatin receptor (SSTR)-directed PET/CTs are essential in patients with gastrointestinal neuroendocrine tumours (GI-NET) undergoing peptide radioreceptor therapy (PRRT).

Conference:

Presenting Author: Weber S

Authors: Weber S, Alwers S, Beissert M, Buck A, Werner R,

Keywords: somatostatin, PRRT, PFS, SUVmean,

#4553 The efficacy of “rechallenge” peptide receptor radionuclide therapy (PRRT) may be inferior to that of the initial PRRT, while the safety profile remains comparable

Introduction: Data on efficacy and adverse events of re-challenge PRRT (re-PRRT) for patients with gastrointestinal neuroendocrine tumours (GI-NETs) are limited.

Conference:

Presenting Author: Heinrich M

Authors: Heinrich M, Lutz F, Alwers S, Däubler C, Buck A,

Keywords: gastrointestinal neuroendocrine tumour, somatostatin receptor directed PET, laboratory parameters, Progression-free survival,

#4382 Sensitivity of endoscopic ultrasound in detecting small gastrointestinal neuroendocrine tumours

Introduction: Small gastrointestinal neuroendocrine tumours (GI-NETs) are often difficult to detect using conventional imaging modalities, leading to delayed diagnosis and suboptimal treatment outcomes. Endoscopic ultrasound (EUS) has emerged as a promising tool for the early detection and precise localisation of these tumours. However, its sensitivity in identifying small lesions remains to be thoroughly evaluated.

Conference:

Presenting Author:

Authors: Xu L, Ye M, Xue B, Tang Q,

Keywords: Endoscopic ultrasound, small gastrointestinal neuroendocrine tumour, early detection, imaging modalities,

#4373 Focal adhesion kinase drives proliferation and invasion in gastrointestinal neuroendocrine tumours via modulation of transformative cell signalling and gene expression

Introduction: Focal Adhesion Kinase (FAK) is a non-receptor protein kinase that localises in both the cytoplasm and nucleus, influencing cell function through its enzymatic and scaffold activities. Through its scaffold function, FAK modulates gene expression epigenetically. Gastrointestinal neuroendocrine tumours (GI-NETs) exhibit a relatively low mutation rate, supporting the hypothesis that these malignancies may be driven epigenetically. Recently, PROTAC (PROteolysis TArgeting Chimeras) technology has enabled selective inhibition and degradation of FAK, providing a novel approach to explore its role in GI-NETs.

Conference:

Presenting Author: Gagliano T

Authors: Toffoli L, Ditsiou A, Moschioni E, Hamm V, Gagliano T,

Keywords: FAK, GI-NET, Cell Signalling, Epigenetics,